Plasma and cerebrospinal fluid activities of tissue plasminogen activator, urokinase and plasminogen activator inhibitor-1 in multiple sclerosis

Fibrinolysis and Proteolysis

Volumn 11, Issue 2, 1997, Pages 109-113

  Akenami, F O T ^a,b   Koskiniemi, M ^a,b   Mustjoki, S ^a,b   Siren, V ^a,b   Farkkila M ^a,b   Vaheri, A ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ADULT; ARTICLE; BLOOD CLOT LYSIS; BRAIN DEVELOPMENT; CELL MIGRATION; CLINICAL ARTICLE; ENZYME IMMUNOASSAY; ENZYME INACTIVATION; HUMAN; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PATHOGENESIS; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; STROKE;

EID: 0030669078     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80103-8     Document Type: Article

References (43)

1. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387.
2. Loskutoff DJ. Type l plasminogen activator inhibitor and its potential influence on thrombolytic therapy. Semin Thromb Hemost 1988; 14: 100-109.
3. Kruithof EKO. Plasminogen activator inhibitors - a review. Enzyme 1988; 40: 113-121.
4. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen K, Nielsen L, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44: 139-266.
5. Pöllänen J, Stephens RW, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 1991; 57: 273-328.
6. Ridker PM, Vaughan DE, Stampfer MK, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-1168.
7. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343: 940-943.
8. Salomaa W, Wu KK, Stinson VL et al. The association of fibrinolytic activity with asymptomatic carotid atherosclerosis: the ARIC study. Circulation 1993; 87: 22.
9. Hamsten A, Wimon B, Défaire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563.
10. Hamsten A, Walldius G, Szaniosi A et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; ii: 3-9.
11. Short CD, Durrington PN, Mallick NP, Bhatnagar D, Hunt NP, Mbewu A. Serum lipoprotein (a) in men with proteinuria due to idiopathic membranous nephropathy. Nephrol Dial Transplant 1992; 7Suppl 1: 109-113.
12. Bartens W, Wanner C. Lipoprotein (a): new insights into an atherogenic lipoprotein. Clin Investigator 1994; 72: 558-567.
13. Chapman MJ, Huby T, Nigon F, Thillet J. Lipoprotein (a): implication in atherothrombosis. Atherosclerosis 1994; 110 Suppl: S 69-75.
14. Gijtenbeek JM, Emeis JJ, Van-der-Sande JJ, Lulf RE. Different types of plasminogen activator activity in human brain tumours: relation with peritumoral oedema? Clin Neurol Neurosurg 1994; 96: 305-309.
15. Sawaya R, Rayford A, Kono S et al. Plasminogen activator inhibitor-1 in the pathogenesis of delayed radiation damage in rat spinal cord in vivo. J Neurosurg 1994; 81: 381-387.
16. Sutton R, Keohane ME, Van der Berg SR, Gonias SL. Plasminogen activator inhibitor-1 in the cerebrospinal fluid as an index of neurological disease. Blood Coagul Fibrinolysis 1994; 5: 167-171.
17. De Vries TJ, Mooy CM, Van Balken MR et al. Components of the plasminogen activation system in uveal melanoma - a clinico-pathological study. J Pathol 1995; 175: 59-67.
18. CarroII PM, Tsirka SE, Richards WG, Frohman MA, Strickland S. The mouse tissue plasminogen activator gene 5' flanking region directs appropriate expression in development and a seizureenhanced response in the CNS. Development 1994; 120: 3173-3183.
19. Garcia-Rocha M, Avila J, Armas-Porte R. Tissue-type plasminogen activator (tPA) is the main plasminogen activator associated with isolated rat nerve growth cones. Neurosci Lett 1994; 180: 123-126.
20. Friedman GC, Seeds NW. Tissue plasminogen activator expression in the embryonic nervous system. Brain Res Dev Brain Res 1994; 81: 41-49.
21. Seeds NW, Williams BL, Bickford PC. Tissue plasminogen activator induction in Purkinje neurons after cerebellar motor learning. Science 1995; 270: 1992-1994.
22. Bizik J, Stephens RW, Grofova M, Vaheri A. Binding of tissuetype plasminogen activator to human melanoma cells. J Cell Biochem 1993; 51: 326-335.
23. Akenami FOT, Sirén V, Koskiniemi M, Siimes MA, Teräväinen H, Vaheri A. Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases. J Clin Pathol 1996; 49: 577-580.
24. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-682.
25. Stephens R, Leung KC, Pöllänen J, Salonen EM, Vaheri A. Microplate immunocapture assay for plasminogen activators and their specific inhibitors. J Immun Meth 1987; 105: 245-251.
26. Stephens R, Alitalo R, Tapiovaara H, Vaheri A. Production of an active urokinase by leukemia cells: A novel distinction from cell lines of active tumors. Leukemia Res 1988; 12: 419-422.
27. Deutsch DG, Mertz ET. Plasminogen: Purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1097.
28. Green GDG, Shaw E. Thiobenzyloxycarbonyl-L-lysinate, substrate for a sensitive colorimetric assay for trypsin-like enzymes. Anal Biochem 1979; 93: 223-226.
29. Akenami FOT, Koskiniemi M, Färkkilä M, Vaheri A. Cerebrospinal fluid plasminogen activator inhibit or-1 in patients with neurological diseases. J Clin Pathol 1997; 50: 157-160.
30. Sugita K, Suzuki N, Shimizu N, Takanashi J, Ishii M, Niimi N. Involvement of cytokines in N-methyl-N'-nitro-Nnitrosoguanidine-induced plasminogen activator activity in acute disseminated encephalomyelitis and multiple sclerosis lymphocytes. EurNeurol 1993; 33: 358-362.
31. Tsirka SE, Rogove AD, Strickland S. Neuronal cell death and tPA. Nature 1996; 384: 123-124.
32. Norton WT, Brosnan CF, Cammer W, Goldmuntz EA. Mechanisms and suppression of inflammatory demyelination. Acta Neurobiol Exp Warsz 1990; 50: 225-235.
33. Dore-Duffy P, Donovan C, Todd RF 3rd. Expression of monocyte activation antigen Mo3 on the surface of peripheral blood monocytes from patients with multiple sclerosis. Neurology 1992; 42: 1609-1614.
34. Dore-Duffy P, Washington R, Dragovic L. Expression of endothelial cell activation antigens in microvessels from patients with multiple sclerosis. Adv Exp Med Biol 1993; 331 : 243-248.
35. Washington R, Burton J, Todd RF 3rd, Newman W, Dragovic L, Dore-Duffy P. The expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. Ann Neurol 1994; 35: 89-97.
36. Romanic AM, Madri JA. The extracellular matrix-degrading proteinases in the nervous system. Brain Pathol 1994; 4: 145-156.
37. Niedbala MJ. Cytokine regulation of endothelial cell extracellular proteolysis. Agents Actions Suppl 1993; 42: 179-193.
38. Stephens RW, Tapiovaara H, Reisberg T, Bizik J, Vaheri A. Alpha-2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells. Cell Regul 1991; 2: 1057-1065.
39. Rao JS, Chen M, Festoff BW. Plasminogen activator inhibitor 1, the primary regulator of fibrinolysis, in the normal human cerebrospinal fluid. J Neurosci Res 1993; 34: 340-345.
40. Andreasen PA, Christensen TH, Huang J-Y, Nielsen LS, Wilson EL, Dan0 K. Hormonal regulation of extracellular plasminogen activators and Mr~54,000 plasminogen activator in human neoplastic cell lines, studied with monoclonal antibodies. Mol Cell Endocrinol 1986; 45: 137-147.
41. 2-antiplasmin and plasminogen activator inhibitor 1 by glioblastoma multiforme in primary organ in culture. J Neurosurg 1990; 73: 234-241.
42. Murphy P, Heart DA. Modulation of plasminogen activator and plasminogen activator inhibitor expression in the human U373 glioblastoma/astrocytoma cell line by inflammatory mediators. Exp Cell Res 1992; 198: 93-100.
43. Rânby M, Sundell IB, Nilsson TK. Blood collection in strong acidic citrate anticoagulant used in a study of dietary influence on basal tPA activity. Thromb Haemost 1989; 62: 917-922.